MaxCyte Inc., a leading cell therapy and gene editing company, announced Thursday that it has acquired SeQure Dx, a specialized gene editing firm, in a deal worth up to $7 million. The move is aimed at enhancing MaxCyte’s scientific capabilities and boosting revenue growth in the expanding cell and gene therapy industry.

Under the agreement, MaxCyte paid $4.5 million in cash at closing for SeQure Dx’s entire issued share capital on a cash-free, debt-free basis. An additional $2.5 million may be paid if SeQure meets certain revenue targets.

SeQure Dx’s Business Model and Financial Performance

In 2024, SeQure Dx generated $1.7 million in revenue but reported a $6.5 million loss, based on unaudited results from Jan. 1 to Nov. 30. Despite these figures, MaxCyte expects SeQure’s financial performance to improve, citing the firm’s March 2024 transition from an assay development and licensing business to a contract service provider.

MaxCyte CEO: Deal Will Drive Innovation in Cell and Gene Therapies

MaxCyte CEO Maher Masoud said the acquisition aligns with the company’s long-term growth strategy.

"Integrating SeQure Dx into MaxCyte’s portfolio will allow us to leverage our expertise and drive advancements in the safety and precision of cell therapies," Masoud said.

He emphasized MaxCyte’s commitment to both organic and inorganic growth, as it continues to develop cutting-edge tools for gene and cell engineering.

SeQure Dx’s Expertise in Gene Editing Validation

SeQure Dx specializes in assays that confirm gene editing accuracy and assess potential risks, which are crucial for advancing safe and effective cell and gene therapies. MaxCyte believes this expertise will enhance its support for therapy developers working on next-generation treatments.

Legal and Financial Details

• The acquisition was announced on the London Stock Exchange (LSE), where MaxCyte is dually listed alongside Nasdaq.
• Counsel information for the transaction was not immediately available.

With this acquisition, MaxCyte is reinforcing its position in the competitive gene editing space, ensuring it remains at the forefront of cell therapy advancements.